Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 70% Improvement Relative Risk Severe case 55% c19ivm.org Loue et al. Ivermectin for COVID-19 EARLY TREATMENT Is early treatment with ivermectin beneficial for COVID-19? Retrospective 25 patients in France Lower mortality (p=0.34) and severe cases (p=0.11), not stat. sig. Loue et al., J. Infectious Diseases and Epidemio.., doi:10.23937/2474-3658/1510202 Favors ivermectin Favors control
Ivermectin and COVID-19 in Care Home: Case Report
Loue et al., J. Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510202
Loue et al., Ivermectin and COVID-19 in Care Home: Case Report, J. Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510202
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small quasi-randomized (patient choice) study with 25 PCR+ patients in a nursing home offered ivermectin, of which 10 chose to be treated. The mean age was 83.5 in the treatment group and 81.8 in the control group. There was lower mortality and fewer serious cases with treatment.
risk of death, 70.0% lower, RR 0.30, p = 0.34, treatment 1 of 10 (10.0%), control 5 of 15 (33.3%), NNT 4.3.
risk of severe case, 55.0% lower, RR 0.45, p = 0.11, treatment 3 of 10 (30.0%), control 10 of 15 (66.7%), NNT 2.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Loue et al., 17 Apr 2021, retrospective quasi-randomized (patient choice), France, peer-reviewed, 2 authors, dosage 200μg/kg single dose.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: ISSN: 2474-3658 Loué and Fardeau. J Infect Dis Epidemiol 2021, 7:202 DOI: 10.23937/2474-3658/1510202 Volume 7 | Issue 4 Open Access Journal of Infectious Diseases and Epidemiology Case Report Ivermectin and COVID-19 in Care Home: Case Report Pierre Loué1 and Christine Fardeau2* Care Home EHPAD, Scarron, Fontenay aux Roses, France Department of Ophthalmology, Reference Center for Rare Diseases, La Pitié-Salpêtrière Hospital, ParisSorbonne University, France 1 2 Check for updates *Corresponding authors: Christine Fardeau, Department of Ophthalmology, Reference Center for Rare Diseases, La PitiéSalpêtrière Hospital, Paris-Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit